Progress of treatment strategies for advanced stages of chronic myeloid leukemia
10.3760/cma.j.cn115356-20240105-00006
- VernacularTitle:慢性粒细胞白血病进展期治疗策略的研究进展
- Author:
Chenxi GU
1
;
Huifang ZHAO
;
Yongping SONG
;
Yanli ZHANG
Author Information
1. 郑州大学附属肿瘤医院血液科，郑州 450003
- Keywords:
Leukemia, myelogenous, chronic, BCR-ABL positive;
Fusion proteins, bcr-abl;
Tyrosine kinase inhibitor;
Molecular targeted therapy
- From:
Journal of Leukemia & Lymphoma
2024;33(8):501-505
- CountryChina
- Language:Chinese
-
Abstract:
Chronic myeloid leukemia (CML) is a clonal hematologic malignancy. In recent years, its treatment mainly involves the application of tyrosine kinase inhibitors (TKI) targeting the BCR::ABL fusion gene, but some patients still develop drug resistance or drug intolerance during TKI treatment and enter into the advanced stages (include accelerated phase and blast crisis phase). This article reviews the research progress of novel TKI drugs, TKI combined regimens and other targeted drugs for treatment of advanced stages of CML.
